Event hosted by New Ear Webinars 

The objective of this webinar is to discuss both the science and regulatory challenges in two areas of research that have great potential to advance the identification and assessment of drug-related adverse events.  ML, a type of artificial intelligence, is showing promise as a tool to enhance drug causality assessments, among other areas in the PV life cycle. Similarly, RWD is providing a wealth of information to help further our understanding and mitigation of drug-related adverse events in the general population. However, there are significant regulatory implications for the use of such data, that will be presented and discussed.

Why Attend this Training? 

By attending this webinar, you will: 

• Understand the significance of ML and RWD in pharmacovigilance

• Understand basic ML terminology